Related Experiment Videos
[Clinical experiences with femovan (Gynera)]
K Brill1, B Düsterberg, M Albring
1Pharma Deutschland Medizin, Schering Aktiengesellschaft, Berlin.
Therapeutische Umschau. Revue Therapeutique
|December 1, 1990
Abstract:
The low dose oral contraceptive Femovan/Gynera which contains 0.03 mg Ethinylestradiol and 0.075 mg Gestoden was examined in several clinical trials. Those trials proved its contraceptive effectiveness, its controlling influence on the menstrual cycle and a low incidence of unwanted side-effects. The data reported are based on the experience of more than 100,000 women representing nearly 600,000 treatment cycles. The results of all the different investigations compiled here underline a high contraceptive effectiveness and excellent control of the cycle when using the respective preparation. The rate of unwanted side-effects was low.
Keywords:
Clinical ResearchClinical TrialsContraceptionContraception ContinuationContraceptive AgentsContraceptive Agents, EstrogenContraceptive Agents, FemaleContraceptive Agents, ProgestinContraceptive EffectivenessContraceptive Methods--beneficial effectsContraceptive Methods--side effectsContraceptive UsageDeveloped CountriesDeveloping CountriesEnglandEthinyl EstradiolEuropeFamily PlanningGermanyGestodeneLatin AmericaMethod AcceptabilityNorthern EuropeOral Contraceptives, Combined--beneficial effectsOral Contraceptives, Combined--side effectsOral Contraceptives--beneficial effectsOral Contraceptives--side effectsPearl's FormulaResearch MethodologyUnited KingdomUse-effectivenessWestern Europe